U.S. Genomics has pioneered commercial applications of single molecule DNA, RNA and protein analysis. The company's innovative technologies which include proprietary technologies for extraction of high grade DNA from complex samples, tagging, microfluidics and genomic mapping, address high value unmet needs in bio-security, human diagnostics, and food and drug contaminant monitoring. Key addressable segments of these markets where the company’s technology offers compelling advantage approach $4.0 billion. The company’s unique technology platform has been funded to date with $100 million from leading blue-chip venture capital firms and contracts with the U.S. Government. more